Patents Assigned to Hybrigenics
  • Patent number: 9435055
    Abstract: The present invention is concerned with a method and a kit for detecting an interaction between a first membrane bound test protein or fragment thereof and a second test protein or fragment thereof which is either membrane bound or soluble with an in vivo genetic system based in yeast, bacterial or mammalian cells. The system makes use of the reconstitution of the split ubiquitin protein.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: September 6, 2016
    Assignee: Hybrigenics Services S.A.S.
    Inventors: Igor Stagljar, Michael Hottiger, Daniel Auerbach
  • Patent number: 8648076
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: February 11, 2014
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Rémi Delansorne, Stefania Vallese, Matteo Colombo
  • Patent number: 8481514
    Abstract: The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D relevant disease comprising administering inecalcitol at doses comprised between 1 mg/day and 100 mg/day to a human patient in need thereof.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: July 9, 2013
    Assignee: Hybrigenics SA
    Inventors: Rémi Delansorne, Jean-François Dufour-Lamartinie
  • Publication number: 20110237644
    Abstract: Use of a polypeptide selected from the group consisting of USP13, USP26, USP38, USP42 or USP46 as a screening tool for an agent for treating cancer.
    Type: Application
    Filed: October 29, 2009
    Publication date: September 29, 2011
    Applicants: Les Laboratoires Servier, Hybrigenics
    Inventors: Olivier Geneste, John Hickman, Frédéric Colland, Laurent Daviet
  • Patent number: 7927813
    Abstract: The invention relates to a method of screening and identifying modulators of the protein interaction between new peptides and anti-apoptotic members of the Bcl-2 protein family. The modulators identified on the basis of this method are administered to patients with cancer in order to bring about apoptotic-type and/or autophagic-type programmed cell death in those patients.
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: April 19, 2011
    Assignees: Les Laboratories Servier, Hybrigenics
    Inventors: Olivier Geneste, John Hickman, Jean-Christophe Rain
  • Patent number: 7875613
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use wherein R3, R4, R5, R6, Y, Het1, T, U, V, W, X, Ru, Rv and Rw are as defined in claim 1.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: January 25, 2011
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Xavier Jacq, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Jean-Christophe Rain, Matteo Colombo
  • Publication number: 20090325883
    Abstract: The invention lies within the field of seeking out and identifying new peptides which interact with anti-apoptotic members of the Bcl-2 protein family, by means of the two-hybrid system. The invention relates to a method of screening and identifying modulators of the protein interaction between those new peptides and anti-apoptotic members of the Bcl-2 protein family. The modulators identified on the basis of this method are administered to patients with cancer in order to bring about apoptotic-type and/or autophagic-type programmed cell death in those patients.
    Type: Application
    Filed: January 31, 2006
    Publication date: December 31, 2009
    Applicants: Les Laboratoires Servier, Hybrigenics
    Inventors: Olivier Geneste, John Hickman, Jean-Christophe Rain
  • Patent number: 7525015
    Abstract: Genes can be introduced into plants that confer desirable traits such as, drought and stress tolerance, insect and pest resistance, as well as environmental qualities such as phyto-remediation. However, possibility for transgene escape to wild and non-transformed species raises commercial and ecological concerns. Disclosed herein are methods and compositions for generating sterile plants for the prevention of transgene escape.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: April 28, 2009
    Assignees: HybriGene, Inc., Rutgers, The State University of New Jersey
    Inventors: Hong Luo, Qian Hu, Kimberly Nelson Vasilchik, John P. Longo, Albert P. Kausch, Barbara Zilinskas, Subha Lakkaraju
  • Patent number: 7462615
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: December 9, 2008
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Rémi Delansorne, Ilaria Peretto, Stefano Vignando
  • Publication number: 20060034860
    Abstract: The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs of agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
    Type: Application
    Filed: May 26, 2004
    Publication date: February 16, 2006
    Applicant: Hybrigenics
    Inventors: Pierre Legrain, Jean-Christophe Rain, Richard Benarous, Stephane Emiliani, Clarissa Berlioz-torrent, Guillaume Blot
  • Patent number: 6977144
    Abstract: The present invention relates to nucleic acids encoding SID® polypeptides which bind selectively to a polypeptide encoded by a pathogenic strain of the hepatitis C virus, as well as to the SID® polypeptides which are encoded by said nucleic acids. The invention also concerns vectors comprising a nucleic acid encoding a SID® polypeptide as well as host cells transformed with such vectors. The invention is also directed to two-hybrid methods which make use of the nucleic acids encoding a SID® polypeptide selected from a pathogenic strain of the hepatitis C virus as well as to methods for selecting molecules which inhibit the binding between a SID® polypeptide and a polypeptide which specifically binds thereto.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: December 20, 2005
    Assignee: Hybrigenics
    Inventors: Pierre Legrain, Simon Whiteside, Jerome Wojcik
  • Patent number: 6916615
    Abstract: The present invention concerns collections of recombinant cell clones derived from a prokaryotic genome, more particularly from Helicobacter pylori genome, useable for two-hybrid systems and methods to produce such collections. The invention further relates to then identification of H. pylori protein-protein interactions and to the application of said collections of recombinant cell clones and said identified proteins interactions to the pharmaceutical and diagnostic field.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: July 12, 2005
    Assignee: Hybrigenics S.A.
    Inventors: Pierre Legrain, Luc Selig, Jean-Christophe Rain
  • Patent number: 6790607
    Abstract: A method for detecting interactions between first and second interacting molecules at variable sensitivity. This variable sensitivity may be obtained by providing for the overexpression of either a bait hybrid protein containing a DNA binding domain (desensitization) or a prey hybrid protein containing the DNA activation domain for a reporter gene (enhanced sensitivity). The use of exogenous activators of one or the other according to the needs of a particular system is readily accomplished.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: September 14, 2004
    Assignee: Hybrigen, Inc.
    Inventors: David N. Edwards, Arlene Leon, David F. Ranney
  • Publication number: 20030232421
    Abstract: The present invention relates to protein-protein interactions of adipocytes, e.g., complexes of such polypeptides, polynucleotides encoding the polypeptides and complexes thereof, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that modulate the protein-protein interactions.
    Type: Application
    Filed: May 6, 2002
    Publication date: December 18, 2003
    Applicant: Hybrigenics
    Inventors: Pierre Legrain, Simon Whiteside, Jen-I Mao, Irina Khrebtukova, Shujun Luo
  • Publication number: 20030188341
    Abstract: Genes can be introduced into plants that confer desirable traits such as, drought and stress tolerance, insect and pest resistance, as well as environmental qualities such as phyto-remediation. However, possibility for transgene escape to wild and non-transformed species raises commercial and ecological concerns. Disclosed herein are methods and compositions for generating sterile plants for the prevention of transgene escape.
    Type: Application
    Filed: February 7, 2003
    Publication date: October 2, 2003
    Applicant: HybriGene, Inc.
    Inventors: Hong Luo, Qian Hu, Kimberly Nelson Vasilchik, John P. Longo, Albert P. Kausch
  • Publication number: 20030148381
    Abstract: The present invention relates to protein-protein interactions involved in deafness or in hearing disorders and/or diseases. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
    Type: Application
    Filed: June 21, 2002
    Publication date: August 7, 2003
    Applicant: Hybrigenics
    Inventors: Laurent Daviet, Pierre Legrain, Christine Petit, Batiste Boeda, Aziz El-Amraoui